Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3652]

ESMO 2017: KEYNOTE-040 evaluates pembrolizumab in head and neck cancer

ESMO 2017: KEYNOTE-040 evaluates pembrolizumab in head and neck cancer

ESMO 2017: Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma

ESMO 2017: Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma

ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer

ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer

ESMO 2017: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months

ESMO 2017: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months

ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer

ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer

Cancer immunotherapy gets a boost by disabling specific T cells

Cancer immunotherapy gets a boost by disabling specific T cells

Immunotherapy combination safe and 62 percent effective in metastatic melanoma patients

Immunotherapy combination safe and 62 percent effective in metastatic melanoma patients

FDG-PET/CT predicts melanoma patients' response to immune checkpoint inhibitor therapy

FDG-PET/CT predicts melanoma patients' response to immune checkpoint inhibitor therapy

European Commission approves pembrolizumab for treatment of advanced bladder cancers

European Commission approves pembrolizumab for treatment of advanced bladder cancers

FDA approves gemtuzumab ozagamicin for treatment of acute myeloid leukaemia

FDA approves gemtuzumab ozagamicin for treatment of acute myeloid leukaemia

More from ecancer